? CANCER RESEARCH CAREER ENHANCEMENT AND RELATED ACTIVITIES Duke Cancer Institute?s Office of Cancer Research Career Development (OCRCD) is committed to the education and training of the next generation of physicians, scientists and health professionals. OCRCD is embedded within the Duke University School of Medicine (SoM) and the Duke University Health System (DUHS), providing a rich, diverse academic environment dedicated to education, training, research, and clinical care of cancer patients. Duke University also has top-ranked graduate and residency programs and a diverse faculty, providing an abundance of qualified and seasoned mentors for our trainees. The specific resources at Duke University and the SoM that form the foundation for OCRCD include; the Duke University Graduate School; graduate programs (Molecular Cancer Biology (MCB), Cell and Molecular Biology (CMB), Development and Stem Cell Biology (DSCB), the Medical Scientist Training Program (MSTP); ACGME-accredited and top-ranked residency programs in Internal Medicine, Pediatrics, Radiation Oncology and Surgery; ACGME-accredited and top-ranked fellowship programs in Gynecological Oncology, Medical Oncology, Neuro-Oncology, Pediatric Oncology and Surgical Oncology; CTSA supported TL1 and KL2 educational programs; the Burroughs Wellcome Fund supported Office of Physician-Scientist Development; the Duke Office of Clinical Research; fifteen cancer focused T32s (7 focused on graduate students and 8 focused on post-doctoral fellows); and an NCI funded P20 focused on Translational Cancer Disparities Research and Education Partnership with North Carolina Central University (a local Historically Black Colleges and Universities). The Office of Health Equity in close partnership with the Duke CTSA, Duke Cancer Institute (DCI) is firmly committed to diversity, inclusion and reducing cancer disparities, further enriching the training environment. Duke University is ranked third in the nation for research universities in matriculating African American students, and underrepresented minorities comprising 20% of our medical students and 13% of our residents. The OCRCD is led by Gerard Blobe, co-leader of the Solid Therapy Tumor (STT) program, a physician- scientist with laboratory and clinical research experience, and director of the Lefkowitz Society, a SoM post- graduate program for physician-scientists. Dr. Blobe reports to the DCI Steering Committee and chairs the OCRCD Oversight Committee. The OCRCD supports cancer-oriented trainees across the training continuum, from high school students, staff to junior faculty, with a comprehensive range of educational, mentoring, and career development resources by leveraging DCI-specific efforts with the broad array of educational and mentoring resources already available in this rich environment, while providing cancer expertise, focus and engagement of DCI faculty to these SoM and DUHS resources. The goal of these efforts is to develop a well- trained and diverse workforce equipped to handle the challenges of cancer research and clinical care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications